Drugs /
svn53-67/m57-klh peptide vaccine
Overview
Clinical Trials
Svn53-67/m57-klh peptide vaccine has been investigated in 3 clinical trials, of which 3 are open and 0 are closed. Of the trials investigating svn53-67/m57-klh peptide vaccine, 2 are phase 1 (2 open) and 1 is phase 2 (1 open).
BIRC5 Expression, HLA-A*02 Positive, and HLA-A*03 Positive are the most frequent biomarker inclusion criteria for svn53-67/m57-klh peptide vaccine clinical trials.
Gastrointestinal neuroendocrine tumors, glioblastoma, and gliosarcoma are the most common diseases being investigated in svn53-67/m57-klh peptide vaccine clinical trials [2].
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].
2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.